Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date
2853 results found
2024 ∙ Ferdinands, J. M. Blanton, L. H. Alyanak, E. Chung, J. R. Trujillo, L. Taliano, J. Morgan, R. L. Fry, A. M. Grohskopf, L. A.
Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: A systematic review and network meta-analysis
Older adults Influenza Efficacy/effectiveness Administration
Rating:
Low
2024 ∙ Abuelazm, M. T. Elzeftawy, M. A. Kamal, M. A. Badr, H. Gamal, M. Aboulgheit, M. Abdelazeem, B. Abd-elsalam, S. Abouzid, M.
Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials
All age groups Malaria Efficacy/effectiveness Safety Administration
Rating:
Critically low
2024 ∙ Ryoo, S. Choi, M. Choi, N. K. Shin, H. S. Woo, J. H. Park, B. J. Oh, S.
Psychiatric adverse events associated with the COVID-19 vaccines approved in the Republic of Korea: a systematic review
South-East Asia South Korea Adolescents Adults Older adults COVID-19 Safety
Rating:
Critically low
2024 ∙ Rizzo, M. Gattino, S. Trombetta, T. Calandri, E. De Piccoli, N.
Psychosocial dimensions of vaccine hesitancy: A systematic review
All age groups Acceptance
Rating:
Not applicable
2024 ∙ de Fougerolles, T. R. Baissas, T. Perquier, G. Vitoux, O. Crepey, P. Bartelt-Hofer, J. Bricout, H. Petitjean, A.
Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives
Europe France Italy Spain United Kingdom All age groups Influenza Economic aspects
Rating:
Not applicable
2024 ∙ Olszewska, B. Zarycza Nowicki, R. J. Sokołowska-Wojdyło, M.
Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review
Adults Older adults COVID-19 Safety
Rating:
Low
2024 ∙ Guo, J. Chen, X. Guo, Y. Liu, M. Li, P. Tao, Y. Liu, Z. Yang, Z. Zhan, S. Sun, F.
Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies
All age groups Influenza Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Yang, X. Shi, N. Liu, C. Zhang, J. Miao, R. Jin, H.
Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies
All age groups Parents/caregivers Acceptance
Rating:
Not applicable
2024 ∙ Nealon, J. Mefsin, Y. M. McMenamin, M. E. Ainslie, K. E. C. Cowling, B. J.
Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis
All age groups COVID-19 Efficacy/effectiveness Administration
Rating:
Critically low
2024 ∙ Mapindra, M. P. Mahindra, M. P. McNamara, P. Semple, M. G. Clark, H. Madsen, J.
Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy
Pregnant women Newborn RSV (Respiratory syncytial virus) Safety Efficacy/effectiveness
Rating:
Critically low
Loading...